Analysts expect Entrada Therapeutics, Inc. to report revenue of 2.02 M for Q3 26, against a range of 1.96 M to 2.09 M. The most recent reported quarter, Q2 26, came in at 898,000.00, a 61.2% miss against the 2.31 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 19.57 M | 37.40 M | 20.56 M | 1.95 M | 1.61 M | 1.30 M | 875,000.00 | 898,000.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 12.64 M | 15.00 M | 11.63 M | 10.62 M | 8.89 M | 7.46 M | 2.90 M | 2.52 M | 2.09 M | 7.98 M | 12.90 M | 2.87 M | 1.83 M | 6.12 M | 9.79 M | 3.56 M | ||||||||||
| Low Estimate | 10.84 M | 12.41 M | 9.70 M | 9.66 M | 7.81 M | 6.42 M | 2.56 M | 2.11 M | 1.96 M | 6.87 M | 10.96 M | 2.44 M | 1.64 M | 5.34 M | 8.54 M | 3.34 M | ||||||||||
| Consensus Estimate | 11.74 M | 13.70 M | 10.66 M | 10.14 M | 8.35 M | 6.94 M | 2.73 M | 2.31 M | 2.02 M | 7.42 M | 11.93 M | 2.65 M | 1.73 M | 5.73 M | 9.16 M | 3.45 M |
Analysts expect Entrada Therapeutics, Inc. to report earnings per share of -0.98 for Q3 26, against a range of -1.02 to -0.94. The most recent reported quarter, Q2 26, came in at -1.01, a 2.0% miss against the -0.99 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.35 | 0.03 | -0.42 | -1.04 | -1.06 | -0.94 | -0.95 | -1.01 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.73 | -0.66 | -0.76 | -0.73 | -0.82 | -1.11 | -0.93 | -0.92 | -0.94 | -0.90 | -0.68 | -0.80 | -0.88 | -0.91 | -0.60 | -0.62 | ||||||||||
| Low Estimate | -0.81 | -0.72 | -0.90 | -0.87 | -0.96 | -1.29 | -1.03 | -1.06 | -1.02 | -1.06 | -0.76 | -0.92 | -0.98 | -0.99 | -0.72 | -0.74 | ||||||||||
| Consensus Estimate | -0.77 | -0.69 | -0.83 | -0.80 | -0.89 | -1.20 | -0.98 | -0.99 | -0.98 | -0.98 | -0.72 | -0.86 | -0.93 | -0.95 | -0.66 | -0.68 |
Pull Wall Street consensus for Entrada Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=TRDA&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "TRDA", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=TRDA&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();